Respiratory Syncytial Virus Diagnostics Market 2025: Rising RSV Infection Rates and Advanced Molecul
The Respiratory Syncytial Virus (RSV) Diagnostics Market accounted for USD 1.3 Billion in 2024 and is projected to reach USD 3.14 Billion by 2035, expanding at a CAGR of 8.35% between 2025 and 2035. The market is witnessing significant momentum due to growing RSV-related hospitalizations, particularly among infants and the elderly, along with increasing adoption of high-sensitivity diagnostic solutions. As global health systems strengthen infectious disease surveillance and early diagnosis protocols, RSV diagnostics are becoming an essential tool in respiratory care.
Request Sample-https://www.metatechinsights.com/request-sample/1657
Market Definition, Objectives, and Overview
Respiratory Syncytial Virus (RSV) is a highly contagious virus affecting the respiratory tract, especially in infants, immunocompromised individuals, and older adults. The diagnostics market includes testing kits, instruments, and reagents used to detect RSV infections through methods such as molecular diagnostics, immunoassays, and rapid antigen tests. The primary objective of the market is to provide early, accurate, and scalable diagnostics to enable timely intervention and reduce disease transmission and severity. With increasing seasonal outbreaks and global awareness, both hospital-based and point-of-care testing are gaining traction.
Key Market Drivers
1. Rising Incidence of RSV Infections in Infants and Elderly
RSV is responsible for over 3 million hospitalizations and nearly 100,000 deaths globally each year, particularly affecting children under five and adults over 65. The CDC estimates that RSV leads to 58,000–80,000 hospitalizations annually in the U.S. among children under 5. These alarming statistics are pushing healthcare providers to adopt early diagnostic tools, especially during the winter months when RSV activity peaks.
2. Demand for Rapid and Accurate Diagnostic Methods
As RSV symptoms overlap with those of influenza and COVID-19, there is growing need for differentiated a